BR0316744A - kinase inhibitors for the treatment of disease - Google Patents

kinase inhibitors for the treatment of disease

Info

Publication number
BR0316744A
BR0316744A BR0316744A BR0316744A BR0316744A BR 0316744 A BR0316744 A BR 0316744A BR 0316744 A BR0316744 A BR 0316744A BR 0316744 A BR0316744 A BR 0316744A BR 0316744 A BR0316744 A BR 0316744A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
disease
treatment
modulate
regulate
Prior art date
Application number
BR0316744A
Other languages
Portuguese (pt)
Inventor
Steven W Andrews
Michael E Garst
Xialing Guo
Jonathan J Hebert
Thomas Malone
Julie A Wurster
Clarence Eugene Hull Iii
Yuan-Xing Guo
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30697502A priority Critical
Priority to US10/307,097 priority patent/US6699863B1/en
Priority to US10/389,416 priority patent/US6747025B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to PCT/US2003/036988 priority patent/WO2004050621A2/en
Publication of BR0316744A publication Critical patent/BR0316744A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"INIBIDORES DE CINASE PARA O TRATAMENTO DE DOENçA". "KINASE INHIBITORS FOR DISEASE TREATMENT". A presente invenção refere-se a moléculas orgânicas capazes de modular transdução de sinal de tirosina cinase a fim de regular, modular e/ou inibir proliferação anormal de célula. The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and / or inhibit abnormal cell proliferation.
BR0316744A 2002-11-27 2003-11-19 kinase inhibitors for the treatment of disease BR0316744A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US30697502A true 2002-11-27 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease
PCT/US2003/036988 WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR0316744A true BR0316744A (en) 2005-10-18

Family

ID=32475339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316744A BR0316744A (en) 2002-11-27 2003-11-19 kinase inhibitors for the treatment of disease

Country Status (7)

Country Link
AU (1) AU2003295658A1 (en)
BR (1) BR0316744A (en)
CA (1) CA2507780A1 (en)
DE (1) DE10393799T5 (en)
ES (1) ES2292329B2 (en)
GB (1) GB2410744B (en)
WO (1) WO2004050621A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013239B1 (en) * 2005-04-28 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Novel compounds for treating inflammatory diseases
WO2007087419A2 (en) 2006-01-24 2007-08-02 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CN104211632B (en) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 Tyrosine kinase 2- indolinone derivatives and their preparation method and application inhibitory activity
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
GB2410744B (en) 2006-04-12
WO2004050621A2 (en) 2004-06-17
GB0511267D0 (en) 2005-07-13
ES2292329B2 (en) 2009-09-16
ES2292329A1 (en) 2008-03-01
DE10393799T5 (en) 2005-10-13
CA2507780A1 (en) 2004-06-17
AU2003295658A1 (en) 2004-06-23
GB2410744A (en) 2005-08-10
WO2004050621A3 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
EA200400355A1 (en) Small organic molecules, which are regulators of cell proliferation
BRPI0206747B1 (en) polynucleotides for use as labels and supplements labels, manufacture and use thereof
BR0308854A (en) Benzazolas replaced and their use as inhibitors of raf kinase
BR0213843A (en) A quinazoline derivative, a process for the preparation of a quinazoline derivative, pharmaceutical composition and use of a quinazoline derivative of
NO20062188A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
BR0116411A (en) Pyrazole compounds useful as protein kinase inhibitors
BR0317715A (en) Compositions and methods of use collajolie
NO20063078A (en) DNA damage repair inhibitors for the treatment of cancer
MA28679B1 (en) Compounds and compositions used as protein kinase inhibitors
BRPI0515986A (en) Combinations of fungicides active substances
BR0013122A (en) Cyclobenzaprine for the treatment of generalized anxiety disorder and compositions cyclobenzaprine
BR0315688A (en) Compounds, pharmaceutical compositions and their use in the treatment or prevention of cell proliferation diseases or metabolic conditions
BRPI0415395A (en) compound, methods for inhibiting protein kinase activity and for treating a patient having a condition which is mediated by protein kinase activity, and composition
BR0203650A (en) Estentor self-articulation
EA200970738A1 (en) Inhibitors of akt
NO20056130A (en) New substituted 3-svovelindoler
NO20082530A (en) Imidazopyraziner as protein kinase inhibitors
BR0308967A (en) quinoline and isoquinoline derivatives, a process for their preparation and their use as inhibitors of inflammation
BRPI0416986A (en) A pharmaceutical preparation comprising an antibody against the EGF receptor
BRPI0606313A2 (en) derivatives of 4- (1H-indol-3-yl) -pyrimidin-2-ylamine, process for their preparation and their use in therapy
NO20052888A (en) Diamintriazoler useful as inhibitors of protein kinases
BRPI0511350A (en) compound induction of apoptosis in a cell methods of sensitizing a cell to an apoptotic signal, inhibition of binding of an IAP protein and a disease and treating cancer and use of a compound
DK1971601T3 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbB type 1 receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EA200301232A1 (en) Arylsulfonamide novel compounds and their use for the treatment of obesity, diabetes, type ii, and disorders of the central nervous system
EA200602100A1 (en) The compounds and methods for inhibiting mitotic progression

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE 6A, E 7A. ANUIDADE(S).

B08K Maintenance of archiving: application remains archived as no request for restauration (art. 87) has been received.

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.